Evolent Health, Inc. (NYSE: EVH), a leader in delivering innovative health solutions for complex conditions, has released its financial results for the first quarter of 2026, showcasing a solid performance amid the ongoing challenges of rising medical costs. The results reflect the company's commitment to enhancing health care affordability while fostering better health outcomes for its clients.

2. Financial Highlights

For the three months ending March 31, 2026, Evolent reported the following key financial metrics:

Revenue: $496,246,000, an increase from $483,649,000 in the same period last year.

Net Loss: $26,632,000, a significant reduction compared to a net loss of $72,250,000 in Q1 2025.

Net Loss Margin: Improved to (5.4)%, down from (14.9)% last year.

Adjusted EBITDA: $22,067,000, a decrease from $36,860,000 year-over-year.

Adjusted EBITDA Margin: Down to 4.4% from 7.6% in the previous year.

These results indicate a favorable trend in reducing losses while growing revenue, positioning Evolent Health for potential profitability in the near future.

3. Membership and Service Suite Performance

Evolent's operational metrics reflect slight changes in the number of members and services utilized during the quarter:

Average Lives on Platform:

Performance Suite: 6,078, down from 6,486.

Specialty Technology and Services Suite: 76,101, slightly down from 77,079.

Administrative Services: 1,118, a decrease from 1,213.

Average Unique Members: 38,903, down from 40,628 in Q1 2025.

The decrease in average lives on the platform can be attributed to market dynamics but is offset by increasing demand for Evolent's specialized health solutions.

4. Revenue Per Member and Medical Expense Ratios

Evolent’s revenue metrics per member provide further insights into its operational efficiency:

Average PMPM Fees:

Performance Suite: Increased to $17.73 from $15.57.

Specialty Technology and Services Suite: Remained stable at $0.35, down from $0.36.

Administrative Services: Decreased to $14.78 from $15.72.

Medical Expense Ratio: Recorded at 93.3%, significantly higher than the 68.0% reported in Q1 2025. Excluding Evolent Care Partners, this ratio remains at 93.3%, compared to 84.0% last year.

This increase in the medical expense ratio highlights the ongoing pressure of medical costs impacting health plans, which continues to drive demand for Evolent's services.

5. Strategic Developments

Evolent is also making strides in expanding its service offerings with two new revenue agreements:

Advanced Imaging Solution: An existing Performance Suite client has signed a contract for this solution, set to launch in Q3 2026, covering approximately 4.5 million lives across Commercial, Medicaid, and Medicare lines of business.

Oncology and Cardiology Expansion: A national payer client is expanding its reach for existing Oncology and Cardiology solutions into new markets, expected to generate over $200 million in annual revenue, also scheduled for Q3 2026 pending regulatory approvals.

6. Looking Ahead

Seth Blackley, Co-Founder and CEO of Evolent, expressed optimism about the company's trajectory. “I am happy with the strong start to the year. We are on track with our plan and have had successful, on-time oncology launches at both Highmark and Aetna,” he stated. As Evolent looks toward 2027 and beyond, the company is focused on maintaining its market leadership in oncology and exploring opportunities in artificial intelligence, while honoring commitments to shareholders, employees, and customers.

Overall, Evolent Health's first quarter results paint a promising picture of a company on an upward trajectory, adapting to market challenges while strategically expanding its offerings in the health care sector.

Original press release